The role of SNARE protein genes in the regulation of Von Willebrand Factor concentration and other coagulation factors

Recruiting

• Conditions: increased inclination to clotting; thrombofilia; 10064477

• Registration Number: NL-OMON36387
• Lead Sponsor: Erasmus MC, Universitair Medisch Centrum Rotterdam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 6 May 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: Not specified
• Target Recruitment: 100

Inclusion Criteria

- Males and females
- 18 - 35 years
- Caucasians

Exclusion Criteria

- Known cardiovascular risk factors, such as hypertension, diabetes,
hypercholesterolemia, obesity (BMI > 30 kg/m2), and a positive family history of CVD.
- Smoking
- Use of medication known to influence VWF levels, such as statins, beta-blockers etc.
(oral contraceptive use is allowed).
- Known malignancies, liver dysfunction or renal dysfunction.
- Pregnancy
- If the participant wishes not to be informed about clinically relevant abnormalities that could be detected during the study.

Study & Design

• Study Type: Observational invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The VWF plasma concentration will change after heavy exercise and this change<br /><br>will differ among genotypes. We expect a 60% increase of VWF plasma levels<br /><br>after heavy exercise and approximately 30% difference between genotypes. </p><br>

Secondary Outcome Measures

Name	Time	Method
<p>Other coagulation parameters and substances secreted by WPBs.<br /><br>To what extent does variation in skin-autofluorescence as a non-invasive marker<br /><br>for accumulation of advanced glycation endproducts and atherosclerotic<br /><br>processes explain the variance in the regulation of VWF concentration?</p><br>